The finalized Japanese version of the Inventory (EDI) has been developed.
Ego-dissolution is a significant aspect of the psychedelic experience.
The EDI is a recognized tool for measuring ego-dissolution.
A rigorous translation and cultural adaptation process was followed to create the Japanese version.
The approved Japanese EDI aims to facilitate research on psychedelic-assisted therapy in Japanese-speaking populations.
Further studies are required to assess the reliability and validity of the translated instrument.
Simplified
AIM: Psychedelics have recently gained attention as potential therapeutic agents for various psychiatric disorders. Previous research has highlighted that a diminished sense of self, commonly termed "" is a pivotal feature of the psychedelic-induced state. While the Ego-Dissolution Inventory (EDI) is a widely acknowledged instrument for measuring this phenomenon, no Japanese version has been available. This study aimed to develop a Japanese version of the EDI.
METHODS: We adhered to the "Guidelines for Best Practices in the Translation and Cultural Modification Process for Patient-Reported Outcomes Instruments: Document from the ISPOR Committee on Translation and Cultural Modification" during our translation approach. Two Japanese psychiatrists independently conducted initial translations, and a consolidated version was achieved via mutual agreement. This version was then back-translated to English and assessed by the original authors for consistency. The repetitive modification process was conducted in continuous dialogues with the original authors until they accepted the concluding back-translated version.
RESULTS: The finalized, approved back-translated version of the EDI is presented in the accompanying figure. In addition, the authorized Japanese version of the EDI is included in the Appendix.
CONCLUSIONS: In this study, we successfully developed the Japanese version of the EDI. This instrument will assist in assessing ego-dissolution experiences associated with psychedelic-assisted therapy among Japanese speakers. Additional studies are necessary to evaluate the reliability and validity of this newly translated instrument.
Full Text
We can’t show the full text here under this license.
Dr. Keisuke Kusudo has received speaker fees from Janssen and Eisai Pharmaceutical within the past 3 years. Dr. Hideaki Tani has received manuscript or speaker fees from Sumitomo Pharma, Janssen Pharmaceutical, Otsuka Pharmaceutical, Takeda, Wiley Japan, and Yoshitomi Yakuhin within the past 3 years. Dr. Kengo Yonezawa declares no conflict of interest. Dr. Shinichiro Nakajima has received grants from Japan Society for the Promotion of Science (18H02755, 22H03002), Japan Agency for Medical Research and Development (AMED), Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Takeda Science Foundation, Uehara Memorial Foundation, Watanabe Foundation, and Osake‐no‐Kagaku Foundation within the past 3 years. Dr. Shinichiro Nakajima has received an investigator‐initiated clinical study grant from Asahi Quality & Innovations, Ltd. Dr. Shinichiro Nakajima has received research support, manuscript fees or speaker's honoraria from Sumitomo Pharma, Meiji‐ Seika Pharma, Otsuka Pharmaceutical, and MSD within the past 3 years. Dr. Hiroyuki Uchida has received grants from Daiichi Sankyo, Eisai, Mochida, Otsuka, and Sumitomo Pharma; speaker's fees from Eisai, Lundbeck, Meiji Seika Pharma, Otsuka, Boehringer Ingelheim Japan, MSD, and Sumitomo Pharma; and advisory board fees from Lundbeck, Sumitomo Pharma, Takeda Pharmaceutical Company, and Boehringer Ingelheim Japan for the past 3 years. Other authors have nothing to disclose. Drs. Shinichiro Nakajima and Hiroyuki Uchida are Editorial Board members of Neuropsychopharmacology Reports and co‐authors of this article. To minimize bias, they were excluded from all editorial decision‐making related to the acceptance of this article for publication.
PubMed
Weekly Psychedelic Science Brief
You found one interesting study. We’ll send the next 7.
Get 7 new psychedelic science papers each week, explained in plain English with direct links to the originals.
